{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:24:09Z","timestamp":1791498249688,"version":"4.3.4"},"reference-count":69,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T00:00:00Z","timestamp":1594252800000},"content-version":"vor","delay-in-days":374,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.jacc.2019.05.016","type":"journal-article","created":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T15:17:17Z","timestamp":1561994237000},"page":"83-99","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":156,"title":["Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing\u00a0PCI"],"prefix":"10.1016","volume":"74","author":[{"given":"Davide","family":"Capodanno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Y.H.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Faxon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher B.","family":"Granger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Vranckx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato D.","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Montalescot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Cannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurien","family":"Ten Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard J.","family":"Gersh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick J.","family":"Angiolillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2019.05.016_bib1","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1161\/CIR.0000000000000558","article-title":"Heart disease and stroke statistics-2018 update: a report from the American Heart Association","volume":"137","author":"Benjamin","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.05.016_bib2","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1160\/TH16-11-0876","article-title":"Stroke prevention in atrial fibrillation: past, present and future. Comparing the guidelines and practical decision-making","volume":"117","author":"Lip","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2019.05.016_bib3","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.advms.2017.06.005","article-title":"Patients with atrial fibrillation and coronary artery disease\u2013double trouble","volume":"63","author":"Michniewicz","year":"2018","journal-title":"Adv Med Sci"},{"key":"10.1016\/j.jacc.2019.05.016_bib4","first-page":"103","article-title":"Dual antiplatelet therapy: appraisal of the ACC\/AHA and ESC focused updates","volume":"72","author":"Capodanno","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.05.016_bib5","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1161\/CIRCULATIONAHA.118.036248","article-title":"Major bleeding rates in atrial fibrillation patients on single, dual, or triple antithrombotic therapy","volume":"139","author":"van Rein","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.05.016_bib6","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2019.05.016_bib7","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.jacc.2015.02.050","article-title":"Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation","volume":"65","author":"Fiedler","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.05.016_bib8","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.05.016_bib9","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual Antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.05.016_bib10","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.05.016_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2019.01.011","article-title":"2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS Guideline for the Management of Patients With Atrial Fibrillation","author":"January","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.05.016_bib12","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS guidelines on myocardial revascularization","volume":"40","author":"Neumann","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2019.05.016_bib13","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2019.05.016_bib14","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2019.05.016_bib15","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1161\/CIRCULATIONAHA.118.034722","article-title":"Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: a North American perspective\u20132018 update","volume":"138","author":"Angiolillo","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.05.016_bib16","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1093\/europace\/euy174","volume":"21","author":"Lip","year":"2019","journal-title":"Europace"},{"key":"10.1016\/j.jacc.2019.05.016_bib17","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(06)68845-4","article-title":"Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial","volume":"367","author":"Connolly","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2019.05.016_bib18","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMoa0901301","article-title":"Effect of clopidogrel added to aspirin in patients with atrial fibrillation","volume":"360","author":"Connolly","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.05.016_bib19","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.05.016_bib20","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.thromres.2016.04.022","article-title":"Hemodynamics associated with atrial fibrillation directly alters thrombotic potential of endothelial cells","volume":"143","author":"Simmers","year":"2016","journal-title":"Thromb Res"},{"key":"10.1016\/j.jacc.2019.05.016_bib21","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","article-title":"2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"37","author":"Kirchhof","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2019.05.016_bib22","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1056\/NEJM199604253341702","article-title":"A\u00a0randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents","volume":"334","author":"Sch\u00f6mig","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.05.016_bib23","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1161\/01.CIR.98.16.1597","article-title":"Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study","volume":"98","author":"Bertrand","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.05.016_bib24","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1161\/01.CIR.98.20.2126","article-title":"Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin\u00a0and ticlopidine trial after intracoronary stenting (MATTIS)","volume":"98","author":"Urban","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.05.016_bib25","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1056\/NEJM199812033392303","article-title":"A\u00a0clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting","volume":"339","author":"Leon","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.05.016_bib26","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41569-018-0049-1","article-title":"Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention","volume":"15","author":"Capodanno","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacc.2019.05.016_bib27","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","volume":"392","author":"Vranckx","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2019.05.016_bib28","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ahj.2016.09.006","article-title":"Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: rationale and design of the TWILIGHT study","volume":"182","author":"Baber","year":"2016","journal-title":"Am Hear J"},{"key":"10.1016\/j.jacc.2019.05.016_bib29","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.05.016_bib30","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1001\/archinternmed.2010.271","article-title":"Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation","volume":"170","author":"Hansen","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2019.05.016_bib31","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.jacc.2015.02.051","article-title":"When is a double better than a TRIPLE? Stenting in patients with atrial fibrillation","volume":"65","author":"Bhatt","year":"2015","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.05.016_bib32","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.ahj.2014.12.006","article-title":"An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention","volume":"169","author":"Gibson","year":"2015","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2019.05.016_bib33","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s11239-018-1703-5","article-title":"Total bleeding with rivaroxaban versus warfarin in patients with atrial fibrillation receiving antiplatelet therapy after percutaneous coronary intervention","volume":"46","author":"Chi","year":"2018","journal-title":"J\u00a0Thromb Thrombolysis"},{"key":"10.1016\/j.jacc.2019.05.016_bib34","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1161\/CIRCULATIONAHA.116.025783","article-title":"Recurrent hospitalization among patients with atrial fibrillation undergoing intracoronary stenting treated with 2 treatment strategies of rivaroxaban or a dose-adjusted oral vitamin K antagonist treatment strategy clinical perspective","volume":"135","author":"Gibson","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.05.016_bib35","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1093\/eurheartj\/ehz059","article-title":"Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial","volume":"40","author":"Oldgren","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2019.05.016_bib36","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/eurheartj\/ehy162","article-title":"Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials","volume":"39","author":"Golwala","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2019.05.016_bib37","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.116.004395","article-title":"Antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention","volume":"9","author":"Angiolillo","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2019.05.016_bib38","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","article-title":"Effect of platelet inhibition with cangrelor during PCI on ischemic events","volume":"368","author":"Bhatt","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.05.016_bib39","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1161\/CIRCULATIONAHA.118.038317","article-title":"Platelet inhibition with cangrelor and crushed ticagrelor in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of the CANTIC Study","volume":"139","author":"Franchi","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.05.016_bib40","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jacc.2016.10.055","article-title":"Cangrelor with and without glycoprotein IIb\/IIIa inhibitors in patients undergoing percutaneous coronary intervention","volume":"69","author":"Vaduganathan","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.05.016_bib41","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1001\/jamacardio.2016.4556","article-title":"Evaluation of ischemic and bleeding risks associated with 2 parenteral antiplatelet strategies comparing cangrelor with glycoprotein IIb\/IIIa inhibitors: an exploratory analysis from the CHAMPION Trials","volume":"2","author":"Vaduganathan","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2019.05.016_bib42","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ahj.2019.02.006","article-title":"Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: an ancillary analysis from the RE-DUAL PCI trial","volume":"212","author":"Lip","year":"2019","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2019.05.016_bib43","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(17)30591-3","article-title":"Tailoring duration of DAPT with risk scores","volume":"389","author":"Capodanno","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2019.05.016_bib44","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1055\/s-0038-1675400","article-title":"Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: a systematic review","volume":"118","author":"Borre","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2019.05.016_bib45","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jacc.2012.06.019","article-title":"Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with atria","volume":"60","author":"Apostolakis","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.05.016_bib46","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.amjcard.2017.07.051","article-title":"Comparison of the CHA2DS2-VASc, CHADS2, HAS-BLED, ORBIT, and ATRIA risk scores in predicting non-vitamin K antagonist oral anticoagulants-associated bleeding in patients with atrial fibrillation","volume":"120","author":"Yao","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2019.05.016_bib47","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1016\/S0140-6736(16)00741-8","article-title":"The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study","volume":"387","author":"Hijazi","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2019.05.016_bib48","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1161\/CIRCULATIONAHA.118.038312","article-title":"Performance of the ABC scores for assessing the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in ENGAGE AF-TIMI 48","volume":"139","author":"Berg","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.05.016_bib49","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1160\/TH17-07-0478","article-title":"Long-term bleeding risk prediction in \u2018real world\u2019 patients with atrial fibrillation: comparison of the HAS-BLED and ABC-Bleeding risk scores","volume":"117","author":"Asunci\u00f3n Esteve-Pastor","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2019.05.016_bib50","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2019.05.016_bib51","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ahj.2018.06.003","article-title":"Safety and efficacy of non\u2013vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: a bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial","volume":"203","author":"Chi","year":"2018","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2019.05.016_bib52","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/j.amjcard.2008.08.021","article-title":"Long-term outcomes in patients undergoing coronary stenting on dual oral antiplatelet treatment requiring oral anticoagulant therapy","volume":"102","author":"Rossini","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2019.05.016_bib53","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1161\/CIRCULATIONAHA.115.018549","article-title":"Stroke prevention in atrial fibrillation in patients with chronic kidney disease","volume":"133","author":"Qamar","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.05.016_bib54","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.jacc.2006.11.044","article-title":"Variability in individual responsiveness to\u00a0clopidogrel","volume":"49","author":"Angiolillo","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.05.016_bib55","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A\u00a0randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2019.05.016_bib56","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1067\/mhj.2000.108239","article-title":"Reduction in the need for hospitalization for recurrent\u00a0ischemic events and bleeding with clopidogrel instead of aspirin","volume":"140","author":"Bhatt","year":"2000","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2019.05.016_bib57","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2174\/138161206776361318","article-title":"Biology and pharmacology of the platelet P2Y12 receptor","volume":"12","author":"Storey","year":"2006","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jacc.2019.05.016_bib58","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1177\/1074248415578172","article-title":"Effects of rivaroxaban on platelet activation and platelet-coagulation pathway interaction: in\u00a0vitro and in\u00a0vivo studies","volume":"20","author":"Perzborn","year":"2015","journal-title":"J\u00a0Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.jacc.2019.05.016_bib59","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/j.jacc.2013.02.036","article-title":"Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation","volume":"61","author":"Sarafoff","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.05.016_bib60","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1161\/CIRCULATIONAHA.117.031164","article-title":"International expert consensus on switching platelet P2Y12 receptor\u2013inhibiting therapies","volume":"136","author":"Angiolillo","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.05.016_bib61","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.jacc.2014.07.957","article-title":"Incidence, source, determinants, and prognostic impact of major bleeding in outpatients with stable coronary artery disease","volume":"64","author":"Hamon","year":"2014","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.05.016_bib62","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/eurheartj\/eht445","article-title":"Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial","volume":"35","author":"Alexander","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2019.05.016_bib63","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1161\/CIRCULATIONAHA.118.036768","article-title":"Open-label randomized trial comparing oral anticoagulation with and without single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond 1 year after coronary stent implantation","volume":"139","author":"Matsumura-Nakano","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.05.016_bib64","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/j.jacc.2010.09.010","volume":"56","author":"Abraham","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.05.016_bib65","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","article-title":"Clopidogrel with or without omeprazole in coronary artery disease","volume":"363","author":"Bhatt","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.05.016_bib66","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ahj.2017.10.009","article-title":"Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: rationale and design of the ENTRUST-AF PCI trial","volume":"196","author":"Vranckx","year":"2018","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2019.05.016_bib67","first-page":"648","article-title":"Rationale and design of the SAFE-A study: SAFety and Effectiveness trial of apixaban use in association with dual antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention","volume":"69","author":"Hoshi","year":"2017","journal-title":"J\u00a0Cardiol"},{"key":"10.1016\/j.jacc.2019.05.016_bib68","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ahj.2018.10.009","article-title":"Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study","volume":"209","author":"Frigoli","year":"2019","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2019.05.016_bib69","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jcin.2017.03.028","article-title":"Triple antithrombotic therapy at the intercept between threats and opportunities","volume":"10","author":"Capodanno","year":"2017","journal-title":"J\u00a0Am Coll Cardiol Intv"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109719352088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109719352088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:23:48Z","timestamp":1760016228000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109719352088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0735109719352088"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2019.05.016","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing\u00a0PCI","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2019.05.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}